Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.64 EUR 0.76% Market Closed
Market Cap: 123m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one HPHA stock under the Base Case scenario is 2.84 EUR. Compared to the current market price of 2.64 EUR, Heidelberg Pharma AG is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HPHA Relative Value
Base Case
2.84 EUR
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

14.5
P/S
P/S
Price to Sales
14.5
vs History
52
vs Industry
39
Median 3Y
14.1
Median 5Y
15.2
Industry
7.2
Forward
11.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-7.9
Industry
21.4
Forward
-6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-7.2
Industry
20.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-9.3
Industry
24.5
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
42
vs Industry
34
Median 3Y
3.1
Median 5Y
3.4
Industry
2.4
More Details
12.7
EV/S
EV/S
Enterprise Value to Sales
12.7
vs History
42
vs Industry
38
Median 3Y
11.9
Median 5Y
12.5
Industry
7.4
Forward
9.8
More Details
15.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.8
vs History
50
vs Industry
31
Median 3Y
14.9
Median 5Y
16.6
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-7.6
Industry
4.1
Forward
-5.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-7.2
Industry
3.8
Forward
-5.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
-7.2
Industry
5.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-6.9
Industry
3.3
More Details
4.5
EV/IC
EV/IC
Enterprise Value to IC
4.5
vs History
80
vs Industry
34
Median 3Y
6.7
Median 5Y
9
Industry
4.4
More Details

Multiples Across Competitors

HPHA Competitors Multiples
Heidelberg Pharma AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Heidelberg Pharma AG
XETRA:HPHA
123m EUR 14.5 -6.6 -5.5 -5.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 547 712.8 -173 705.9 -210 934.2 -208 527.2
US
Abbvie Inc
NYSE:ABBV
370.7B USD 6.6 87.5 17.1 25.8
US
Amgen Inc
NASDAQ:AMGN
169.7B USD 5.1 41.5 16.7 29.5
US
Gilead Sciences Inc
NASDAQ:GILD
133.4B USD 4.6 278 10.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.3B USD 11.7 -241.4 26.5 27.7
US
Epizyme Inc
F:EPE
94.1B EUR 1 927.6 -491.9 -535.6 -521.3
AU
CSL Ltd
ASX:CSL
123B AUD 5.1 28.1 17.3 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.2B USD 5.1 16.4 10.7 12
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.2 -55.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
36.6B USD 16.3 -131.7 -290.8 -197.7
P/S Multiple
Revenue Growth P/S to Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average P/S: 3 322 702.5
14.5
14%
1
FR
Pharnext SCA
OTC:PNEXF
36 547 712.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 927.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
28%
0.6
P/E Multiple
Earnings Growth PEG
DE
Heidelberg Pharma AG
XETRA:HPHA
Average P/E: 90.3
Negative Multiple: -6.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 705.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.5
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.5
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
278
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.9 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -131.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average EV/EBITDA: 16.5
Negative Multiple: -5.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 934.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.7
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.7
14%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -290.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average EV/EBIT: 21.7
Negative Multiple: -5.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.8
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.5
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -197.7 N/A N/A

See Also

Summary
HPHA intrinsic value, competitors valuation, and company profile.
DCF Valuation
HPHA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HPHA stock valuation using valuation multiples.
Wall Street Estimates
HPHA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HPHA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 240,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.